Standout Papers

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evid... 2020 2026 2022 2024859
  1. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020)
    Raju Vaddepally, Prakash Kharel et al. Cancers

Immediate Impact

3 by Nobel laureates 7 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
1 intermediate paper

Works of Rohan Garje being referenced

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
2020 Standout

Author Peers

Author Last Decade Papers Cites
Rohan Garje 525 1048 179 411 73 1.7k
Kristen A. Marrone 719 1395 110 439 71 1.9k
Haiyong Wang 510 766 137 501 105 1.6k
Leyre Zubiri 422 1239 96 393 56 1.9k
Aurélie Bertaut 563 809 316 351 101 1.7k
Erika Rijavec 683 1036 141 477 92 1.7k
Tom Wei‐Wu Chen 724 1337 158 382 90 1.9k
Daniel L. Suzman 777 1237 258 343 56 1.9k
Xiuyu Cai 632 974 269 422 96 2.0k
Laura Pala 506 1270 259 331 66 2.0k
Qingyuan Zhang 536 1162 115 362 70 1.7k

All Works

Loading papers...

Rankless by CCL
2026